Stay updated on Elranatamab in Refractory Multiple Myeloma Clinical Trial
Sign up to get notified when there's something new on the Elranatamab in Refractory Multiple Myeloma Clinical Trial page.

Latest updates to the Elranatamab in Refractory Multiple Myeloma Clinical Trial page
- Check2 days agoChange DetectedThe page’s revision line has been updated from v3.5.2 to v3.5.3. This reflects a new release version in the site history without altering study content.SummaryDifference0.1%

- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedRevision v3.5.2 was added to the history, and Revision v3.5.0 was removed.SummaryDifference0.1%

- Check23 days agoNo Change Detected
- Check45 days agoChange DetectedRevision v3.5.0 was added to the Record History and revision v3.4.3 was removed.SummaryDifference0.1%

- Check52 days agoChange DetectedAdded Revision: v3.4.3 and removed Revision: v3.4.2 from the history, indicating a site version update.SummaryDifference0.1%

- Check80 days agoChange DetectedThe page shows an added Revision: v3.4.2 and the removal of prior notices including the lapse-in-funding message and the v3.4.1 revision notice. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check87 days agoChange DetectedA site-wide notice about government funding and operating status was added. The page version was updated from v3.4.0 to v3.4.1.SummaryDifference0.4%

Stay in the know with updates to Elranatamab in Refractory Multiple Myeloma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Elranatamab in Refractory Multiple Myeloma Clinical Trial page.